| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PPARG |
| Uniprot No | P37231 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-477aa |
| 氨基酸序列 | MTMVDTEMPFWPTNFGISSVDLSVMEDHSHSFDIKPFTTVDFSSISTPHYEDIPFTRTDPVVADYKYDLKLQEYQSAIKVEPASPPYYSEKTQLYNKPHEEPSNSLMAIECRVCGDKASGFHYGVHACEGCKGFFRRTIRLKLIYDRCDLNCRIHKKSRNKCQYCRFQKCLAVGMSHNAIRFGRMPQAEKEKLLAEISSDIDQLNPESADLRALAKHLYDSYIKSFPLTKAKARAILTGKTTDKSPFVIYDMNSLMMGEDKIKFKHITPLQEQSKEVAIRIFQGCQFRSVEAVQEITEYAKSIPGFVNLDLNDQVTLLKYGVHEIIYTMLASLMNKDGVLISEGQGFMTREFLKSLRKPFGDFMEPKFEFAVKFNALELDDSDLAIFIAVIILSGDRPGLLNVKPIEDIQDNLLQALELQLKLNHPESSQLFAKLLQKMTDLRQIVTEHVQLLQVIKKTETDMSLHPLLQEIYKDLY |
| 预测分子量 | 86.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Structural basis for ligand activation of the human peroxisome proliferator-activated receptor γ"** by Nolte, R.T. et al. (1998), *Nature*
- 摘要：通过X射线晶体学解析PPARγ配体结合域与激动剂复合物的三维结构，揭示配体结合如何引发受体构象变化，促进共激活因子招募。
2. **"Antidiabetic thiazolidinediones are high-affinity ligands for the nuclear receptor PPARγ"** by Lehmann, J.M. et al. (1995), *Journal of Biological Chemistry*
- 摘要：首次证实抗糖尿病药物噻唑烷二酮类(TZDs)为PPARγ的合成配体，通过激活受体增强脂肪细胞分化及胰岛素敏感性。
3. **"Expression and purification of recombinant PPARγ for functional analysis"** by Uppenberg, J. et al. (1998), *Journal of Molecular Biology*
- 摘要：报道大肠杆菌表达系统中高效制备重组PPARγ配体结合域的方法，并通过生物物理手段验证其结合活性，为结构研究奠定基础。
4. **"15-Deoxy-Δ12.14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ"** by Forman, B.M. et al. (1995), *Cell*
- 摘要：鉴定前列腺素衍生物PGJ2为PPARγ内源性配体，揭示其在脂肪生成和炎症调控中的双重作用。
PPARG (Peroxisome Proliferator-Activated Receptor Gamma) is a nuclear receptor protein that plays a central role in regulating adipocyte differentiation, lipid metabolism, and glucose homeostasis. As a member of the ligand-activated transcription factor superfamily, PPARG forms heterodimers with retinoid X receptor (RXR) to modulate gene expression by binding to specific peroxisome proliferator response elements (PPREs) in target genes. It contains two functional domains: a DNA-binding domain and a ligand-binding domain that interacts with fatty acids, prostaglandins, and synthetic agonists like thiazolidinediones (TZDs).
Recombinant PPARG proteins are engineered through molecular cloning techniques, typically expressed in bacterial (E. coli) or mammalian systems to preserve post-translational modifications. These proteins serve as critical tools for studying PPARG's structural dynamics, ligand-receptor interactions, and downstream signaling pathways. Researchers utilize purified recombinant PPARG in electrophoretic mobility shift assays (EMSAs), fluorescence polarization assays, and X-ray crystallography to investigate its molecular mechanisms.
Pharmaceutically, PPARG is a therapeutic target for metabolic disorders. TZDs, which activate PPARG, enhance insulin sensitivity in type 2 diabetes by promoting adipogenesis and lipid storage in adipose tissue rather than liver or muscle. However, clinical use is limited by side effects, driving research into partial agonists or selective PPARG modulators (SPPARγMs). Recombinant PPARG also aids in identifying natural ligands and assessing gene variants linked to obesity, atherosclerosis, and cancer. Mutations in PPARG are associated with lipodystrophy, hypertension, and altered cancer cell proliferation, underscoring its multifaceted roles in physiology and disease. The development of recombinant forms has accelerated drug discovery and mechanistic studies, bridging gaps between cellular pathways and therapeutic interventions.
×
